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Abstract
Studies of the biofilm life cycle can identify novel targets and strategies for improving
biofilm control measures. Of particular interest are dispersal events, where a
subpopulation of cells is released from the biofilm community to search out and
colonize new surfaces. Recently, the simple gas and ubiquitous biological signaling
molecule nitric oxide (NO) was identified as a key mediator of biofilm dispersal
conserved across microbial species. Here, we review the role and mechanisms of NO
mediating dispersal in bacterial biofilms, and its potential for novel therapeutics. In
contrast to previous attempts using high dose NO aimed at killing pathogens, the use
of low, non-toxic NO signals (picomolar to nanomolar range) to disperse biofilms
represents an innovative and highly favourable approach to improve infectious disease
treatments. Further, several NO-based technologies have been developed that offer a
versatile range of solutions to control biofilms, including: (i) NO-generating
compounds with short or long half-lives and safe or inert residues, (ii) novel
compounds for the targeted delivery of NO to infectious biofilms during systemic
treatments, and (iii) novel NO-releasing materials and surface coatings for the
prevention and dispersal of biofilms. Overall the use of low levels of NO exploiting
its signaling properties to induce dispersal represents an unprecedented and promising
strategy for the control of biofilms in clinical and industrial contexts.
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Increased antimicrobial tolerance in biofilms is the basis for chronic
infections and failed antibiotic therapies
Antibiotic and antimicrobial strategies have traditionally been evaluated using
suspension cultures of homogenous planktonic bacteria. However, in nature most
bacteria live predominantly in heterogeneous multicellular biofilm communities
encapsulated in a self-produced matrix of extracellular polymeric substances (EPS),
while the free-swimming planktonic cells appear to be associated with a dispersal
phase necessary to colonise new habitats. The biofilm lifestyle confers bacteria with
greatly increased resistance compared to their planktonic counterparts, showing up to
10,000 fold higher tolerance towards immune defences, biocides and antibiotics [1-3],
rendering biofilm infections extremely difficult to eradicate. Thus the formation of a
biofilm often leads to persistent and chronic infections, which greatly increase
morbidity and mortality. Bacterial biofilms are estimated to be the cause of 80% of all
clinical infections (e.g. reviewed in [4]). The mechanisms of biofilm tolerance are still
not fully understood but appear to involve a combination of physical effects together
with specific and non-specific genetic determinants. Firstly, the biofilm EPS matrix
provides a protective barrier by both reducing the penetration of antibiotics [5] and
accumulating extracellular defence compounds such as -lactamase enzymes [6], as
well as guarding biofilm bacteria from macrophage engulfment and killing [7].
Secondly, within the biofilm, bacteria exhibit a high level of tolerance, either: (i) via
expression of biofilm-specific traits such as periplasmic antibiotic-binding
polysaccharides [8]; (ii) due to upregulation of enzymes to protect against endogenous
oxidative stress [9]; or (iii) as a result of genetic modifications. The latter may occur
in a non-specific manner due to increased frequency of mutations in biofilms that can
lead to new resistance traits, e.g. constitutive expression of efflux pumps [10], or via
3

horizontal gene transfer when an invading pathogen acquires resistance genes from a
commensal community [11]. Further, rapid adaptive induction of antibiotic resistance
genes in cells at the biofilm peripheries can also serve to protect the rest of the biofilm
community [12]. Thirdly, tolerance in biofilms is enhanced by the presence of a high
number of persister cells. Nutrient gradients established within biofilm structures lead
to starvation responses inducing a number of cells to switch to a transient antibiotictolerant persister phenotype, which can survive antibiotic treatments and rapidly
resume growth once the treatment is stopped [13]. Antibiotic treatments are not only
inefficient at controlling biofilms but exposure to sub-inhibitory concentrations of
many antibiotics can also result in increased biofilm formation (reviewed in [14]), a
process that is likely to have clinical relevance in numerous infectious diseases.
Accordingly there is an urgent need to develop novel therapeutics and strategies to
control biofilms and overcome biofilm resistance.

Inducing the natural biofilm dispersal response to control biofilmrelated infections
One promising approach towards novel biofilm control measures is to study and target
endogenous mechanisms that regulate the biofilm life cycle (Fig. 1A). Biofilm
formation is a multi-stage process that involves the coordinated differentiation of cells.
Following initial attachment, mediated by bacterial motility and cell surface
appendages, such as pili and fimbriae that interact with abiotic and biotic surface
materials, bacteria produce abundant EPS comprised of polysaccharides, proteins,
extracellular nucleic acids, lipids and ions such as Ca2+, which irreversibly commit the
cells to the surface. During maturation, biofilms establish complex 3D structures
comprised of highly differentiated bacteria, rendering the biofilm environment and the
4

bacterial communities highly heterogeneous, including steep nutrient and oxygen
gradients. The final stage of biofilm development involves the coordinated release of
differentiated, motile, chemotactic cells known as dispersal cells (reviewed in [15]).
These specialized cells can colonize new surfaces and restart the biofilm life cycle. In
several bacteria, biofilm dispersal correlates with the programmed death of a
subpopulation of cells in mature microcolonies [16]. Surviving cells are then able to
escape through break out points, leaving behind hollow structures in the biofilm.
Dispersal events are generally thought to benefit the biofilm by releasing
phenotypically diverse cells for the colonisation of new surfaces and by limiting
overcrowding in a densely populated and genetically diversified mature biofilm [17].

Several molecular triggers have been identified that can induce the transition from a
sessile, surface associated or suspended biofilm phenotype to a free-swimming
dispersal phenotype, including: (i) environmental and physiological cues such as
nutrient [18-20] or oxygen [21] availability, low concentrations of nitric oxide (NO)
[22-24], iron levels [25, 26], and

D-amino

acids [27]; (ii) cell-cell communication

signals such as quorum sensing (QS) acyl-homoserine lactone signals [28],
autoinducing peptides [29] and diffusible fatty acids [30, 31]; and (iii) intracellular
messengers such as cyclic di-GMP (c-di-GMP), which has emerged as a central
element in the complex regulatory network controlling the switch between biofilm
and planktonic bacteria [32], as well as cAMP, which was previously known to
control the stringent response and was recently found to be implicated in biofilm
formation and dispersal [33, 34]. Upon sensing a dispersal cue, bacteria can activate a
range of cellular effectors that lead to dispersal, including the secretion of enzymes
and surfactants that solubilise and degrade EPS components [35-37]. Finally,

5

induction of the dispersal response activates expression of motility mechanisms such
as flagella and pili and proteins involved in chemotaxis [38, 39]. Dispersal is thus a
highly regulated process that requires recruitment of the cellular machinery and
energy resources to escape from the biofilm.

Manipulation of the endogenous biofilm development program, by inducing dispersal
signals, has become a preferred strategy for developing novel control strategies in
recent years. For instance, 2-aminoimidazole derivatives targeting QS have been
designed and found to disperse established biofilms [40, 41]. Proof of concept studies
showed that in vivo manipulation of c-di-GMP levels can effectively clear (by
decreasing c-di-GMP) or prolong (by increasing c-di-GMP) Pseudomonas aeruginosa
infections in murine models [42, 43]. Modification of the BdcA protein to enhance its
c-di-GMP binding, thus reducing the intracellular c-di-GMP concentration, caused
nearly complete removal of biofilms via dispersal in vitro [44]. Of particular interest
is NO, a simple and versatile dispersal signal that is highly conserved across biofilm
species. Much progress has been made in recent years to design efficient NO delivery
strategies making it an outstanding candidate for novel therapeutic strategies. This
review focuses on the discovery and use of NO for inducing biofilm dispersal.

Recent discovery of a key physiological signal for biofilm dispersal:
nitric oxide (NO)
NO is produced endogenously during the biofilm life cycle to induce dispersal and
trigger the transition to a planktonic lifestyle
NO is a ubiquitous gas and reactive lipophilic radical that can freely diffuse into cells.
Its signaling role in regulating dispersal of bacterial biofilms was first discovered
6

while studying the biofilm life cycle of P. aeruginosa, where it was found to be
produced at the same time and location as cell death and dispersal [22] (Fig. 1A). The
use of a range of fluorescent dyes for detecting specific reactive oxygen and nitrogen
species first indicated NO as the key mediator of cell death. This was confirmed by
genetic studies demonstrating that dispersal events in biofilms are regulated by the
endogenous production of NO [22]. A mutant strain unable to express nitrite
reductase (NIR) required for production of NO did not show cell death and dispersal,
whereas a mutant strain unable to scavenge NO (impaired in production of NO
reductase, NOR) exhibited increased cell death and dispersal compared to the wild
type [22]. Further, it was found that adding NO back to biofilms, by using donor
compounds that spontaneously release NO in solution, showed that NO, at low, nontoxic concentrations in the picomolar to nanomolar range, triggered dispersal and the
transition to the planktonic mode of growth. Importantly, exposure to low doses of
NO restored the sensitivity of biofilm and dispersed bacteria towards several classes
of antimicrobial agents, greatly increasing their efficacy (Fig. 2).

NO-mediated dispersal is conserved across species
Dispersal responses to NO have been observed in a range of monospecies biofilms.
For instance addition of NO donors was shown to induce dispersal in biofilms of P.
aeruginosa, Escherichia coli, Vibrio cholerae, Bacillus licheniformis, Serratia
marcescens, Fusobacterium nucleatum [23], Shewanella woodyi [24], Neisseria
gonorrhoeae [45] and a marine Pseudoalteromonas species [46], and in Vibrio
fischeri addition of a NO scavenger prevented dispersal of aggregates [47]. Exposure
to nitrite inhibited biofilm formation by Staphylococcus aureus, presumably through
generating NO and inducing dispersal [48]. In Bacillus subtilis [49], changes in
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endogenous production of NO resulted in loss of biofilm biomass. In Legionella
pneumophila, a NO responsive sensor protein was found to mediate reduction in
biofilm biomass [50]. Nitrifying biofilms also appear to be responsive to NO, for
instance Nitrosomonas europaea biofilms were previously found to disperse in
response to low NO levels [51]. In Pseudomonas putida studies showed that
heterologous expression of a NO synthase (NOS) enzyme resulted in increased
motility and biofilm dispersal [52]. Further, NO can also induce dispersal in
multispecies biofilms. Addition of low dose (20-500 nM) NO donors caused dispersal
of mixed species microbial biofilms formed in drinking water and recycled-water
systems and on reverse osmosis water filtration membranes [23]. Suspended biofilm
aggregates in expectorated sputum from chronically infected cystic fibrosis (CF)
patients were dispersed by using NO donors [53]. Thus NO-mediated biofilm
dispersal appears to be well conserved across bacterial species. Paradoxically, some
studies have demonstrated the opposite effect where the addition of NO stimulated
biofilm formation, for instance in Shewanella oneidensis [54] and the rhizobacterium
Azospirillum brasilense [55]. It is possible that NO may not induce dispersal
responses in some species, for instance in the context of host-microbe symbiotic or
mutualistic relationships [56]. Intriguingly, disaggregation, dispersal and inhibition of
attachment induced by NO have also been observed in several eukaryotic organisms,
including fungi [23, 57], amoeba [58] and algal zoospores [59] (Table 1), which
suggests that NO may be an ancient and highly conserved regulator of dispersal [60].

NO signaling involves the secondary messenger c-di-GMP
To elucidate the regulatory mechanisms involved in NO-mediated biofilm dispersal,
transcriptomic analysis of the cellular response to low levels of NO were performed in
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P. aeruginosa biofilms. These studies revealed that NO signaling is part of a global
regulatory network that controls the switch between biofilm and planktonic
phenotypes and involves the secondary messenger c-di-GMP [39]. NO was found to
decrease intracellular levels of c-di-GMP and stimulate phosphodiesterase (PDE)
activity in cell-free extracts, the latter suggesting posttranslational regulation [39].
The ubiquitous messenger c-di-GMP functions as a central regulator of many
important bacterial processes, including biofilm formation, virulence and dispersal
(recently reviewed in [32, 61]). Intracellular levels of c-di-GMP are controlled
through the opposing activities of diguanylate cyclases (DGC), for the synthesis of cdi-GMP, and PDEs, for its degradation. These are encoded by a conserved GGDEF
domain and EAL or HDGYP domain containing genes, respectively. Many bacterial
genomes encode multiple DGCs and PDEs often associated with other putative
signaling domains, suggesting that their enzymatic activities may be responsive to
different environmental cues. Downstream cellular targets of c-di-GMP include
repression of EPS production, activation of EPS degrading enzymes and motility. A
number of effectors of c-di-GMP signaling have been identified, such as transcription
factors, PilZ domain and degenerate GGDEF and EAL domain-containing proteins, as
well as mRNA riboswitches [61]. A link between NO and c-di-GMP has been
established in several bacterial species in addition to P. aeruginosa, including S.
woodyi [24], L. pneumophila [50], Pseudoalteromonas atlantica [62] and E. coli [63].
In E. coli, NO was found to induce motility and decrease surface attachment upon
binding to the transcription repressor NsrR [64], although it is not clear if NsrR is
linked to c-di-GMP or whether it operates via an independent pathway in E. coli.
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In P. aeruginosa several c-di-GMP specific PDEs have been identified that appear to
be involved in NO-mediated dispersal, including DipA, RbdA and NbdA [65, 66].
Further, NO signaling was shown to require the chemotaxis regulator BdlA [39], as
well as the periplasmic protease LapG (dispersal in response to NO donors in in vitro
batch and continuous flow P. aeruginosa biofilm assays was fully inhibited in the
lapG knockout mutant strain compared to wild type, unpublished data), which in P.
putida and Pseudomonas fluorescens was found to be repressed by a c-di-GMP
receptor protein LapD and activated when intracellular c-di-GMP levels decreased [67,
68]. Although a receptor for NO associated with a c-di-GMP PDE remains to be
identified in P. aeruginosa, such regulatory systems have been identified in S. woodyi
[24]. S. woodyi encodes a heme nitric oxide/oxygen binding (HNOX) protein, which
when complexed with NO binds to and activates a PDE enzyme resulting in dispersal
(Fig. 1B). HNOX domains are conserved hemoproteins that are highly sensitive to
NO, producing responses at femtomolar levels in Clostridium botulinum [69]. They
are found in several Gram-negative and Gram-positive bacterial genomes and are
often associated with a DGC or PDE [70]. However many bacterial strains known to
disperse in response to NO, including P. aeruginosa and E. coli, do not have HNOX
domain suggesting other systems can sense and transduce NO signals. Similarly,
Gram-positive strains such as S. aureus do not possess any GGDEF, EAL or HDGYP
domain, suggesting that in some organisms NO-mediated dispersal may operate via a
signaling cascade independent of the secondary messenger c-di-GMP.
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Dysregulation of NO production by the host immune system leads to
chronic infection and disease
NO has been known to play an important role in the immune system and host
defences against pathogenic bacteria for some time. Early studies showed that host
tissues produce NO using nitric oxide synthase (NOS) enzymes from L-arginine after
recognition of bacterial invasion [71-73]. Both constitutively expressed (cNOS) and
inducible (iNOS) NOS are involved in immunity. In macrophage and epithelial cells,
iNOS enzymes are activated by bacterial lipopolysaccharides (LPS) and inflammatory
cytokines (e.g. IFN-, IL-1, and TNF-) [74].

In some cases, impairment of NOS function can lead to infectious disease. The cause
of NOS malfunction may originate from the host or from the bacteria. For example,
invading pathogens such as E. coli [75] or Salmonella typhimurium [76] can avoid
host defences by secreting effectors that inhibit iNOS. Helicobacter pylori was found
to secrete arginase to inhibit NO production in gastric mucosa [77]. In the oral cavity,
NO production normally occurs during plaque deposition but in patients affected by
smoking, where NO levels are reduced, higher bacterial counts are observed [78].

Cystic fibrosis (CF) lungs
NOS activity and generation of NO is required for clearance of infections in the
respiratory tract [79]. In the lungs of patients suffering from CF, epithelial cells fail to
produce NO in response to pathogen invasion and bacterial LPS sensing [80, 81].
Impaired NO production may be due to reduced NOS expression, including both
iNOS [80, 82, 83] and possibly cNOS [84], as well as reduced availability of the NOS
substrate L-arginine, possibly due to increased arginase activity in CF airways [85].
11

This inability to produce NO in response to pathogen invasion in CF patients appears
to play a major role in the establishment of chronic infections, and compromised NOS
activity has even been suggested as the primary reason for the poor antimicrobial
defence of CF lungs [86]. In vitro studies using human airway epithelial cells from a
CF patient showed reduced P. aeruginosa adhesion and infection in CF cells
transfected with human iNOS cDNA compared to cells without iNOS [87]. Further, in
these experiments while recombinant iNOS did not reduce internalisation of adhered
bacteria, internalised cells were efficiently killed, suggesting that NO production
mostly regulates adhesion as well as killing of cells that have infiltrated the
epithelium.

NO and inflammation
NO plays an important role in regulating inflammatory responses. Dysregulation of its
production in chronically infected host tissues can lead to immunopathology [88]. In
healthy patients, NO can act as an autoregulatory feedback inhibitor serving to limit
tissue damage after the onset of inflammation. At high levels, NO can inhibit iNOS
expression in macrophages and terminate the inflammatory process [89]. The
mechanisms underlying this regulation have recently been uncovered and found to
involve S-nitrosylation of the inflammasome protein NLRP3 [90]. Thus it was
suggested that impaired iNOS activity could potentially exacerbate autoimmune
diseases including colitis, arthritis and multiple sclerosis [91]. In CF patients, lack of
iNOS has also been linked to inflammation disorders [92]. Due to its role in
inflammation and because it can be measured quickly and non-invasively in the
respiratory airways, exhaled NO has become an important diagnostic marker for
inflammatory airway conditions such as asthma and bronchitis [93, 94].
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Adjunctive low dose NO combined with antibiotics: a promising new
clinical strategy for biofilm control
Treatments to induce biofilm dispersal with NO and effectively inactivate dispersed
bacteria with antibiotics
The ability of NO to induce the signaling cascade involving stimulation of PDE
activity and decreased intracellular c-di-GMP leading to dispersal of biofilms offers
great promise for developing novel and efficient therapeutics for controlling biofilmrelated infections and for overcoming biofilm resistance. While exposure to low doses
of NO alone appears to be non-toxic to bacteria, the released planktonic cells and cells
still residing on surfaces both show increased susceptibility to a range of antibiotics
and antimicrobials [23, 39, 95]. Thus NO-based anti-biofilm strategies probably
benefit from combined treatments with standard antibiotic therapies to clear infections.
Before considering NO as a standalone therapeutic, further studies are needed to
determine whether exposure to low doses of NO in a host environment can facilitate
recruitment of immune defences capable of clearing the dispersed cells.

Biofilm-related diseases are highly diverse as biofilms can form on both living tissues,
e.g. lungs, nose (rhinosinusitis), urinary tract, ears (otitis media), heart (endocarditis),
oral cavity (plaque, gingivitis) or wounds, as well as abiotic surfaces, e.g. dialysis
catheters, prosthetic implants or contact lenses [4]. This variety of conditions makes it
difficult to develop antibiofilm treatments that could be applied for treating multiple
diseases. NO-based strategies to disperse biofilms will benefit from a broad range of
delivery methods (reviewed below) that can be specifically adapted on a case-by-case
basis.
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At higher levels, NO may be effective at killing biofilms
At physiological concentrations, in the picomolar and nanomolar range, NO serves
multiple signaling roles in both the host and pathogenic organisms. However, at
higher concentrations NO can be converted to a number of more reactive derivatives,
known collectively as reactive nitrogen species, which can have cytostatic and
cytotoxic effects on pathogens as well as host cells [96]. These can cause damage to
nucleic acids and proteins through nitrosylation (adding an NO group) or nitration
(adding an NO2 group) of amine, thiol and tyrosine residues, as well as metal centres
[96]. At elevated concentrations, the high diffusivity and multiple modes of action of
NO make it a broad-spectrum antimicrobial agent that could kill biofilms of Gramnegative and Gram-positive bacteria. In vitro experiments showed that exposure to
200 ppm NO gas (~8 µM NO) for up to 5 h could fully eradicate cultures of clinical
isolates of S. aureus, methicillin-resistant S. aureus (MRSA), E. coli, Group B
Streptococcus, P. aeruginosa and Candida albicans [97]. The potential of intermittent
exposure to high levels of NO gas has been assessed in animal trials using rats. NO
was delivered at 160 ppm (~7 µM NO) for 30 min every 4 h to rats with P.
aeruginosa airway infection, and the results showed that the NO treatment was able to
reduce the infection by more than 2 log [98]. Exposure to NO gas at 500 ppm (~20
µM NO) for 60 s every 24-48 h of external wounds colonised by S. aureus led to
faster wound healing by 30%, compared to controls [99]. Wound dressings that
release NO levels typically at 500 ppm appeared to be efficient at killing biofilms of
nosocomial pathogens Acinetobacter baumannii, MRSA, and P. aeruginosa when
assessed in in vitro experiments [100]. The use of toxic NO has also been investigated
for treatment of urinary tract infections, where the addition of 10 mM ascorbate and

14

nitrite at 50 µM to 5 mM, which under these conditions generate equimolar NO,
cleared E. coli infections in artificial urine and in an urinary tract model [101, 102].
Another study demonstrated the effectiveness of NO-charged catheters, typically
releasing 2 to 60 µM NO, in preventing E. coli infections [103].

Several concerns have been raised when using NO as a bactericidal agent. Firstly, at
high concentrations NO can be toxic to tissues and inhibit healing. Because NO can
act as an immunosuppressant that limits inflammation, high levels could prematurely
halt healing and reduce macrophage activity against infections. Further, during wound
treatments excessive NO could be inhibitory to angiogenesis, decreasing endothelial
cell and lymphocyte proliferation [104, 105]. Side effects of nitrosative stress in host
tissues include the generation of carcinogenic N-nitrosamines [106]. In the lungs, high
levels of NO can transfer to the blood and cause methaemoglomia [107]. Recently the
safety of delivery and the physiologic effects of intermittent exposure to 160 ppm NO
gas three times daily for 30 min for 5 days have been assessed in clinical trials. While
a first cohort of healthy individuals appeared to tolerate the treatment well [108], in a
second trial with CF patients, detrimental side effects were reported in several of the
eight patients who received NO that included increased methaemoglomia, dry mouth,
and one case of reduced lung function (forced expiratory volume in 1 s, FEV1 max <
10%) [109]. Second, at elevated levels, NO may induce defence mechanisms in
bacteria rendering them more tolerant to antibiotics. Thus in P. aeruginosa, while
exposure to low concentrations of NO induced biofilm dispersal, treatment with
higher concentrations in the micromolar to millimolar range resulted in increased
biofilm formation, presumably as an adaptive response to protect against nitrosative
stress [22]. In B. subtilis, 5 s exposure to 30 µM NO was found to enhance defence
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against oxidative stress by depleting free cysteine and activating catalase [110]. In
Salmonella, 750 µM NO donor spermine NONOate was found to block respiration,
which induced an accumulation of NADH that protected against oxidative stress [111].
The same treatment was also shown to impair energy-dependent drug uptake after
causing an arrest in respiration, which then led to increased resistance towards
aminoglycoside antibiotics [112]. Finally, at high levels NO may directly react with
antibiotic compounds leading to their inactivation [113]. Therefore the effectiveness
of toxic levels of NO to kill biofilms may be strongly dependent on the bacterial
species and infection conditions and may elicit undesirable secondary effects that
could compromise clearance of the infection. In contrast, increased antibiotic
resistance is not expected when using low, non-toxic concentrations of NO in the
picomolar to nanomolar range to induce dispersal.

NO delivery methods
Due to its reactivity towards a wide range of molecules, including metalloproteins,
heme and non-heme iron centres, thiols and amines, as well as oxygen and free radical
species such as superoxide (O2–•), NO has a half-life of only a few seconds in
biological systems [114]. In order to be effective, NO needs to be available in the
immediate vicinity of pathogenic biofilms. The method of delivery of NO to
infectious biofilms is therefore crucial and can conceivably be achieved by several
means.
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Use of NO gas
If applicable, NO can be directly applied as a gas to infection sites exposed to air. NO
gas has been used to treat skin infections, most notably leg ulcers [115]. Inhaled NO
gas was approved as therapeutic agent by the US Food and Drug Administration
(FDA) in 1999 and the European Medicine Evaluation Agency and European
Commission in 2001. It has since been used as a pulmonary vasodilator in treating
pulmonary hypertension, including in patients with chronic obstructive pulmonary
disease (COPD) [116, 117]. However, the effect of inhaled NO on bacterial infections
during these treatments was not investigated. Previous studies by two different
research teams showed that exposure to 40 ppm NO in air [118] or 10 ppm NO in
100% oxygen [119] for 24 h reduced P. aeruginosa infiltration and helped clear lung
infections in rats, decreasing bacterial load by 1.7 and 2 log, respectively. In the latter
study, 10 ppm NO was also found to increase influx of inflammatory cells into the air
space of infected rats [119]. Recently, the first clinical trial was conducted to evaluate
the use of low dose inhaled NO gas combined with standard intravenous ceftazidime
and tobramycin antibiotic therapy for the disruption of P. aeruginosa biofilms in 12
patients with CF. The results demonstrated that patients who received NO gas at 5-10
ppm (~200 nM NO) for 8 h daily during 7 days concomitant with standard
ceftazidime and tobramycin treatments showed significant reductions, by 3.5 log in
the number of Pseudomonas biofilm aggregates and marginal improvement in lung
function (FEV1 and forced vital capacity, FVC) compared to patients who received a
placebo [120]. These data suggest that using NO as adjunctive therapy may be highly
beneficial for the treatment of CF-related biofilm infections.
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Stimulation of endogenous NO production
The delivery of NO to infectious biofilms should be achievable by stimulating
endogenous production, either from the biofilm cells or from the surrounding infected
tissues. In bacteria, NO is produced from NIR enzymes in denitrifying as well as nondenitrifying organisms [121], or from NOS enzymes using L-arginine as substrate
[122]. Nitrate, nitrite and L-arginine have all been shown to enhance susceptibility of
P. aeruginosa in biofilms to antibiotics by up to 2 log reduction in colony-forming
units (CFU), presumably through an NO-mediated mechanism [123]. Exposure of S.
aureus to nitrite, which was suggested to generate NO, prevented the formation of in
vitro biofilms [48]. Addition of acidified nitrite, which can generate NO either
spontaneously or from NIR activity, was found to effectively control P. aeruginosa, S.
aureus and Burkholderia cepacia biofilms [124, 125], although in these cases high
concentrations of nitrite (15 mM) were used and NO acted via a toxic, killing effect
on biofilms. In preliminary clinical studies, treatments with nebulized L-arginine in
CF patients infected with P. aeruginosa resulted in sustained improvement in lung
function associated with significantly increased NOS activity within lung tissues,
suggesting that the NO augmentation could potentially reduce the bacterial infection
[126, 127]. However in these studies, the effect of increased

L-arginine

on P.

aeruginosa growth was not investigated and will need to be confirmed in subsequent
trials.

Use of NO donors
The most versatile option for the delivery of NO is to use NO-donor molecules that
can liberate NO in vivo. Release of NO from donors can occur either spontaneously,
upon activation by enzymatic activity or through activation under select chemical
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conditions, e.g. pH. In general, the effective concentrations of NO delivered to the
biofilms are estimated to be 100-1000 times lower than the concentration of NO
donor used (Fig. 3, [23]). NO donors could potentially be administered in a variety of
formulations, including tablets, ointments or nebulisers. Much progress has been
made in developing usable NO donors and a large variety of compounds have been
described in various reviews (e.g. [128, 129]). The metal nitrosyl sodium
nitroprusside (SNP) and the organonitrate nitroglycerin are FDA-approved drugs that
have been used for more than 50 years in the treatment of hypertension. SNP at 500
nM has been shown to effectively disperse various single species biofilms as well as
multispecies biofilms, including those in CF sputum [22, 23, 53]. S-nitrosoglutathione
(GSNO), a naturally occurring S-nitrosothiol, is also used clinically as a vasodilator,
including in the lungs of CF patients [130, 131]. An important and highly versatile
class of NO donors are the diazeniumdiolates (NONOates). Originally created as a
laboratory curiosity, this class of compounds has evolved in the past 15 years into a
vast range of compounds with wide ranging chemical properties and NO release
profiles that are potentially useful in many short- or long-term healthcare applications
[132] (Fig. 3). NONOate chemistry allows for storage of NO as part of an engineered
molecule whose framework can be controlled to tune the level of NO storage, rate of
NO release and molecule size. The compounds can be used to modify polymers and
nanoparticles and can also be engineered to include prodrug moieties for targeted NO
delivery (see sections below). Finally, dispersal of P. aeruginosa biofilms by longlived aminoxyl free radicals (nitroxides), which are sterically hindered analogues of
nitric oxide, has been demonstrated [133].
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Targeted delivery of NO by using β-lactam prodrug antibiotics
Due to its short half-life in biological systems and its potential for non-selective
reactivity towards many host targets, the use of donor compounds that spontaneously
release NO in solution would often not be ideal for treating biofilm infections. The
compounds could potentially have side effects and these typically polar chemicals
would be difficult to deliver to biofilms. An innovative new class of NO-donor
prodrugs was recently described that can liberate NO upon specific activation by
bacterial enzymes [95, 134] (Fig. 4). The cephalosporin-3’-diazeniumdiolate
compounds consist of a β-lactam analogue, cephalosporin, that provides a scaffold to
prevent release of NO from an NONOate donor until activated by a substrate-tolerant,
bacteria-specific enzyme β-lactamase. The modified cephalosporins were rationally
designed to selectively release highly unstable NONOates (t1/2 = 2.8 s-2 min for NO
generation) following reaction with β-lactamase, and thus trigger biofilm dispersal.
The lead compound, DEA NONOate-Cephalosporin Prodrug (DEACP) was
synthesised and found to be highly stable in solution and release NO upon reaction
with commercially available β-lactamase penicillinase as well as whole cell extracts
from P. aeruginosa that produce β-lactamases. Interestingly, release of NO was also
triggered by non-β-lactamase-producing E. coli extracts suggesting that the
compounds can also be activated by transpeptidases, the target enzymes of β-lactam
antibiotics. These compounds were effective at dispersing biofilms of several
pathogenic species including mixed species biofilms from CF sputum, and when used
in combination with tobramycin and ciprofloxacin greatly improved the outcome of
the antibiotic therapy [53, 95]. In these experiments, the use of DEACP at 10 µM was
found to be more effective than at 100 µM, increasing tobramycin and ciprofloxacin
treatments by 1.8 and 1.5 log reduction in CFU, respectively [95]. The novel and
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flexible synthetic chemistry route developed for DEACP was used to access five
additional analogues carrying variations in both the acyl-amido side chain (R1) and
O2-alkyldiazeniumdiolate (R2) portions [134] (Fig. 5). The compounds showed
activity similar to DEACP. Two compounds, DEACP and PyrroCP were tested for
cytotoxicity in L929 murine fibroblast cells and showed no toxicity at 50 µM
(DEACP) or 100 µM (PyrroCP, unpublished data), which suggests an excellent
therapeutic window. The use of β-lactam-based prodrugs for the targeted delivery of
NO to biofilms is immensely attractive as many cephalosporins have previously and
continue to be used clinically [135]. The simple modification to incorporate a
diazeniumdiolate NO donor may represent an effective method for treating biofilmbased chronic infections.

NO polymers and nanoparticles
Nanoparticle drug delivery has been widely studied as a means for increasing drug
solubility and tissue specificity. The utility of nanoparticles arises from their various
physicochemical properties (e.g., hydrophobicity, charge, size), which can be tuned
by varying synthetic precursors and procedures. Silica- and gold-based nanoparticles
have been developed that release low or high levels of NO [136-139] and show
effectiveness against biofilms [140]. Nanoparticles also offer the advantage that they
can be combined with other active molecules, such as antimicrobial agents, e.g. long
chain quaternary ammonium salts [141]. NO-releasing polypropylenimine dendrimers
have been developed which allow higher levels of NO release per ‘backbone’
molecule over traditional NO donors [142]. NO releasing polymers and nanoparticles
could be used either as coatings to prevent biofilm formation on surfaces such as
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catheters, prosthetic implants or contact lenses as well as industrial surfaces, or
delivered in formulation either systemically or topically to treat biofilms on tissues.

NO-QS inhibitor dual-action hybrid compounds
Another important signaling pathway in biofilms is the quorum sensing (QS) system.
QS regulates virulence, biofilm formation and dispersal in a range of organisms [143].
NO and QS-mediated regulation appear to share common molecular mechanisms, as
exemplified in P. aeruginosa where QS deficient strains were found to accumulate
more NO [144, 145]. This raises the intriguing possibility of interfering with multiple
biofilm regulatory pathways using combinations of QS inhibitors and NO donors as a
strategy towards therapeutics for controlling biofilms and bacterial virulence. A wide
range of synthetic and natural product-based QS inhibitors have been identified in the
last two decades, including the halogenated furanones isolated from the marine red
algae Delisea pulchra which show highly potent QS inhibition and virulence
attenuation activities [146]. Recently, novel dual-action furanone-NO donor hybrid
compounds have been designed and synthesized. Two compounds were found to have
both QS inhibition and NO releasing properties and were effective antibiofilm agents
[147].

Surface modification for biofilm prevention and dispersal
The formation of biofilms on abiotic surfaces is a major clinical concern as biofilms
on prosthetic implants, catheters or contact lenses, for example, can act as reservoirs
for pathogenic bacteria leading to chronic and severe infections. NO releasing
materials and coatings were originally developed to prevent platelet aggregation and
improve biocompatibility of biological implants, such as vascular grafts (artificial
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blood conduits) [148, 149]. Newer sol-gel NO releasing coatings based on NONOates
have been developed that are compatible with artificial prosthetic implants and
display antibacterial properties. The coatings were capable of inhibiting adhesion of
biofilm bacteria, e.g. P. aeruginosa, S. aureus, and S. epidermidis [150, 151]. Polymer
coatings that allow for modulation of NO release, controlled either by light, (e.g. Snitrosothiols [152] or metal nitrosyls [153]) or by an electric pulse [154] have also
been developed. Finally, coatings capable of catalytically generating NO via
conversion of endogenous substrates such as S-nitrosothiols or nitrite are attractive for
long-term applications since they are not limited by a finite reservoir of NO
embedded in the surface [155, 156].

Future perspectives
The role of NO as a signaling molecule is vast. First discovered in the 1980s for its
role in regulating vasodilation via the activation of soluble guanylate cyclase, NO has
since emerged as a universal signal regulating a plethora of physiological functions in
living organisms [157]. Its importance in human physiology was recognised with a
number of awards and NO was named ‘molecule of the year’ by Science in 1992
[158]. The diffusivity of NO across cell membranes and its reactivity towards a range
of target sites stand out as unique properties in signal transduction that allow rapid
spreading and amplification of an initial cue and the coordination of a subset of
adjacent cells. The signaling role of NO in regulating biofilm dispersal across
microbial species offers an unprecedented opportunity to develop novel treatments to
induce biofilm dispersal and improve treatments for chronic infections. Since the
mechanisms linked to dispersal involve non-toxic activation of a signaling pathway
there is reduced pressure for the evolution and spreading of variant bacteria. Thus,
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resistance is not expected to arise from low-dose NO treatments. As the signaling
pathways are further elucidated, novel markers both from infectious biofilms and host
tissues will be identified that will facilitate the evaluation of novel biofilm-dispersing
compounds in in vivo studies.

A range of NO donor compounds are already available that can be used as adjunctive
therapies to improve antibiotic treatments. In addition, novel carriers, including
nanoparticles and dual-action hybrid drugs, polymer coatings and prodrugs
specifically designed to release NO to biofilm infection sites are being investigated. In
the future, new compounds will be designed that exhibit multiple actions, including
release of NO signals and/or other agents interfering with various effectors of the
signaling cascades regulating dispersal and virulence, combined with potent antibiotic
activity. Further, given the extreme simplicity of NO as an active ingredient, it may be
possible to develop a wide range of targeted release chemistries for the precise
delivery of NO signals to specific pathogenic bacteria, while leaving intact the
commensal microbial community.
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Figures and Tables

Fig. (1). (A) The biofilm life cycle: oxygen (O2) and nutrient gradients are present in
the mature biofilm leading to production of NO signals that trigger cell death and
dispersal. (B) NO signals activate phosphodiesterase (PDE) activity, which leads to
decreased c-di-GMP levels and enhanced dispersal. In Shewanella woodyi, direct
binding of NO to an H-NOX sensor stimulating PDE activity has been demonstrated
[24].

Fig. (2). Add-back of NO to established biofilms using the NO donor sodium
nitroprusside (SNP) triggers dispersal and increases susceptibility to various
antimicrobial treatments: hydrogen peroxide (H2O2), tobramycin, sodium dodecyl
sulphate (SDS) and ultraviolet light (UV). Partly reproduced from [22].

Fig. (3). (A) Representatives from the NONOate (diazeniumdiolate) class of NO
donors. (B) Spontaneous NO release from 100 µM PROLI/NO, DEA/NO or
SPER/NO in 0.1 M Tris buffer (pH 7.4). Measurements were obtained using an NO
selective electrode. Arrow indicates addition of the NO scavenger 2-phenyl-4,4,5,5,tetramethylimidazoline-1-oxyl 3-oxide (PTIO).

Fig. (4). Novel prodrug strategy for biofilm-targeted NO delivery [95]. (A)
Cephalosporins bearing O2-alkyldiazeniumdiolates at the 3’ position release
NONOate anions following reaction with bacterial -lactamases. (B) Electrode
measurements of NO release from DEACP in the presence of penicillinase. Arrows
from left to right indicate addition of: 100 µM DEACP, 0.05 U / ml penicillinase, 0.1
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U / ml penicillinase and NO scavenger PTIO. (C) Schematic drawing of DEACP
activation and NO-induced dispersal in biofilms. Red stars denote biofilm lactamase enzymes.

Fig. (5). Chemical structures of synthesised cephalosporin-3’-diazeniumdiolates. Half
lives of the appended diazeniumdiolates in aqueous buffer at pH 7.4 are given.
Compound numbers correspond to [134].

Table 1. List of microbial species dispersed by NO.
Manipulation of NO
Microbial species

Description

Ref
levels

Single species biofilms
Pseudomonas aeruginosa

Gram –ve opportunistic

NO donors SNP,

[22, 23,

pathogen

nitroxides, MAHMA

66, 133,

NONOate. Mutants

159]

in NIR and NOR
NO donor SNP

[23, 64]

NO donor SNP

[23]

Gram –ve opportunistic

NO donors SNP,

[23]

pathogen

SNAP

Gram –ve pathogen, agent

NO donors SNP,

of cholera

SNAP, GSNO

Bacillus licheniformis

Gram +ve soil bacterium

NO donor SNP

Shewanella woodyi

Gram –ve marine bacterium NO donor DETA

Escherichia coli

Gram –ve opportunistic
pathogen

Fusobacterium nucleatum

Gram –ve anaerobic oral
pathogen

Serratia marcescens

Vibrio cholerae

[23]

[23]
[24]
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NONOate
Neisseria gonorrhoeae

Gram –ve pathogen

NO donor SNP

[45]

Pseudoalteromonas sp.

Gram –ve marine bacterium NO donor SNP

[46]

Vibrio fischeri

Gram –ve marine bacterium NO scavenger PTIO

[47]

Staphylococcus aureus

Gram +ve pathogen

[48]

strain NCIMB 2021

NO source sodium
nitrite

Bacillus subtilis

Gram +ve opportunistic

Mutant in NOS

[49]

Gram –ve pathogen, agent

Mutant in H-NOX

[50]

of legionellosis

domain

Gram –ve autotroph

Low NO gas

[51]

Heterologous

[52]

pathogen
Legionella pneumophila

Nitrosomonas europaea

nitrifier
Pseudomonas putida

Gram –ve soil bacterium

expression of NOS
Multispecies biofilms
Mixed species biofilms

From water distribution

NO donors SNP,

systems and filtration

PROLI NONOate

[23]

membranes
Mixed species biofilm

From cystic fibrosis sputum

NO donor SNP

[53]

Yeast; oral and genital

NO donor SNP

[23]

Yeast; opportunistic

NO source L-

[57]

pathogen

arginine; NOS

aggregates
Eukaryotes
Candida albicans

infections
Candida tropicalis

inhibitor L-NAME
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Dictyostelium discoideum

Soil amoeba

NOS inhibitor L-

[58]

NIO, NO gas, NO
scavenger
oxyhemoglobin
Ulva linza

Algal zoospores

NO donor SNAP,

[59]

NO scavenger PTIO

NIR, nitrite reductase; NOR, NO reductase; SNP, sodium nitroprusside; SNAP, Snitroso-N-acetylpenicillamine; GSNO, S-nitrosoglutathione; NOS, NO synthase; LNAME, Nω-nitro-L-arginine methyl ester; L-NIO, L-N5-iminoethyl ornithine; PTIO, 2phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide.
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Fig. (1). (A) The biofilm life cycle: oxygen (O2) and nutrient gradients are present in
the mature biofilm leading to production of NO signals that trigger cell death and
dispersal. (B) NO signals activate phosphodiesterase (PDE) activity, which leads to
decreased c-di-GMP levels and enhanced dispersal. In Shewanella woodyi, direct
binding of NO to an H-NOX sensor stimulating PDE activity has been demonstrated
[1].

Fig. (2). Add-back of NO to established biofilms using the NO donor sodium
nitroprusside (SNP) triggers dispersal and increases susceptibility to various
antimicrobial treatments: hydrogen peroxide (H2O2), tobramycin, sodium dodecyl
sulphate (SDS) and ultraviolet light (UV). Partly reproduced from [2].

Fig. (3). (A) Representatives from the NONOate (diazeniumdiolate) class of NO
donors. (B) Spontaneous NO release from 100 µM PROLI/NO, DEA/NO or
SPER/NO in 0.1 M Tris buffer (pH 7.4). Measurements were obtained using an NO
selective electrode. Arrow indicates addition of the NO scavenger 2-phenyl-4,4,5,5,tetramethylimidazoline-1-oxyl 3-oxide (PTIO).

Fig. (4). Novel prodrug strategy for biofilm-targeted NO delivery [3]. (A)
Cephalosporins bearing O2-alkyldiazeniumdiolates at the 3’ position release
NONOate anions following reaction with bacterial β-lactamases. (B) Electrode
measurements of NO release from DEACP in the presence of penicillinase. Arrows
from left to right indicate addition of: 100 µM DEACP, 0.05 U / ml penicillinase, 0.1
U / ml penicillinase and NO scavenger PTIO. (C) Schematic drawing of DEACP
activation and NO-induced dispersal in biofilms. Red stars denote biofilm βlactamase molecules.

Fig. (5). Chemical structures of synthesised cephalosporin-3’-diazeniumdiolates. Half
lives of the appended diazeniumdiolates in aqueous buffer at pH 7.4 are given.
Compound numbers correspond to [4].

Table 1. List microbial species dispersed by NO.
Microbial species

Description

Pseudomonas aeruginosa

Gram –ve opportunistic
pathogen

Escherichia coli

Gram –ve opportunistic
pathogen
Gram –ve pathogen, agent
of cholera
Gram +ve soil bacteria
Gram –ve opportunistic
pathogen
Gram –ve anaerobic oral
pathogen
Yeast, oral and genital
infections
Gram –ve marine bacteria

Vibrio cholerae
Bacillus licheniformis
Serratia marcescens
Fusobacterium nucleatum
Candida albicans
Shewanella woodyi
Neisseria gonorrhoeae
Pseudoalteromonas sp.
strain NCIMB 2021
Vibrio fischeri
Staphylococcus aureus

Gram –ve pathogen
Gram –ve marine bacteria

Bacillus subtilis

Gram +ve opportunistic
pathogen
Gram –ve pathogen, agent
of legionellosis
Gram –ve autotroph
nitrifier
Gram –ve soil bacteria

Legionella pneumophila
Nitrosomonas europaea
Pseudomonas putida
Multispecies biofilms from
water distribution systems
and filtration membranes
CF sputum biofilm
aggregates
Candida tropicalis

Gram –ve marine bacteria
Gram +ve pathogen

Yeast, opportunistic
pathogen

Dictyostelium discoideum

Soil amoeba

Ulva linza

Algae zoospores

Manipulation of NO
levels
NO donors SNP,
nitroxides, MAHMA
NONOate. Mutants
in NIR and NOR
NO donor SNP

Ref
[2, 5-8]

[5, 9]

NO donors SNP,
SNAP, GSNO
NO donor SNP
NO donors SNP,
SNAP
NO donor SNP

[5]

NO donor SNP

[5]

NO donor DETA
NONOate
NO donor SNP
NO donor SNP

[1]

NO scavenger PTIO
NO source sodium
nitrite
Mutant in NOS

[12]
[13]

Mutant in H-NOX
domain
Low NO gas

[15]

Heterologous
expression of NOS
NO donors SNP,
PROLI NONOate

[17]

NO donor SNP

[18]

NO source Larginine; NOS
inhibitor L-NAME
NOS inhibitor LNIO, NO gas, NO
scavenger
oxyhemoglobin
NO donor SNAP,
NO scavenger PTIO

[19]

[5]
[5]
[5]

[10]
[11]

[14]

[16]

[5]

[20]

[21]

NIR, nitrite reductase; NOR, NO reductase; SNP, sodium nitroprusside; SNAP, Snitroso-N-acetylpenicillamine; GSNO, S-nitrosoglutathione; NOS, NO synthase; LNAME, Nω-nitro-L-arginine methyl ester; L-NIO, L-N5-iminoethyl ornithine; PTIO,
2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide.

1.
Liu N, Xu Y, Hossain S, et al. Nitric oxide regulation of cyclic di-GMP
synthesis and hydrolysis in Shewanella woodyi. Biochemistry 2012; 51: 2087-99.
2.
Barraud N, Hassett DJ, Hwang SH, et al. Involvement of nitric oxide in
biofilm dispersal of Pseudomonas aeruginosa. J Bacteriol 2006; 188: 7344-53.
3.
Barraud N, Kardak BG, Yepuri NR, et al. Cephalosporin-3'diazeniumdiolates: targeted NO-donor prodrugs for dispersing bacterial biofilms.
Angew Chem-Int Edit 2012; 51: 9057-60.
4.
Yepuri NR, Barraud N, Shah Mohammadi N, et al. Synthesis of
cephalosporin-3'-diazeniumdiolates: biofilm dispersing NO-donor prodrugs activated
by β-lactamase. Chem Commun 2013; 49: 4791-3.
5.
Barraud N, Storey MV, Moore ZP, et al. Nitric oxide-mediated dispersal in
single- and multi-species biofilms of clinically and industrially relevant
microorganisms. Microb Biotechnol 2009; 2: 370-8.
6.
Li Y, Heine S, Entian M, et al. NO-induced biofilm dispersion in
Pseudomonas aeruginosa is mediated by an MHYT domain-coupled
phosphodiesterase. J Bacteriol 2013; 195: 3531-42.
7.
de la Fuente-Núñez C, Reffuveille F, Fairfull-Smith KE, et al. The effect of
nitroxides on swarming motility and biofilms, multicellular behaviors in
Pseudomonas aeruginosa. Antimicrob Agents Chemother 2013.
8.
Barnes RJ, Bandi RR, Wong WS, et al. Optimal dosing regimen of nitric
oxide donor compounds for the reduction of Pseudomonas aeruginosa biofilm and
isolates from wastewater membranes. Biofouling 2013; 29: 203-12.
9.
Partridge JD, Bodenmiller DM, Humphrys MS, et al. NsrR targets in the
Escherichia coli genome: new insights into DNA sequence requirements for binding
and a role for NsrR in the regulation of motility. Mol Microbiol 2009; 73: 680-94.
10.
Potter AJ, Kidd SP, Edwards JL, et al. Thioredoxin reductase is essential for
protection of Neisseria gonorrhoeae against killing by nitric oxide and for bacterial
growth during interaction with cervical epithelial cells. J Infect Dis 2009; 199: 227-35.
11.
Werwinski S, Wharton JA, Iglesias-Rodriguez MD, et al. Electrochemical
sensing of aerobic marine bacterial biofilms and the influence of nitric oxide
attachment control. Mater Res Soc Symp Proc 2011; 1356.
12.
Davidson SK, Koropatnick TA, Kossmehl R, et al. NO means 'yes' in the
squid-vibrio symbiosis: nitric oxide (NO) during the initial stages of a beneficial
association. Cell Microbiol 2004; 6: 1139-51.
13.
Schlag S, Nerz C, Birkenstock TA, et al. Inhibition of staphylococcal biofilm
formation by nitrite. J Bacteriol 2007; 189: 7911-9.
14.
Schreiber F, Beutler M, Enning D, et al. The role of nitric-oxide-synthasederived nitric oxide in multicellular traits of Bacillus subtilis 3610: biofilm formation,
swarming, and dispersal. BMC Microbiol 2011; 11: 111.
15.
Carlson HK, Vance RE, Marletta MA. H-NOX regulation of c-di-GMP
metabolism and biofilm formation in Legionella pneumophila. Mol Microbiol 2010;
77: 930-42.
16.
Schmidt I, Steenbakkers PJ, op den Camp HJ, et al. Physiologic and proteomic
evidence for a role of nitric oxide in biofilm formation by Nitrosomonas europaea
and other ammonia oxidizers. J Bacteriol 2004; 186: 2781-8.
17.
Liu P, Huang Q, Chen W. Heterologous expression of bacterial nitric oxide
synthase gene: a potential biological method to control biofilm development in the
environment. Can J Microbiol 2012; 58: 336-44.

18.
Cathie K, Howlin RP, Sukhtankar P, et al. Low dose nitric oxide as adjunctive
therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis. ID
week; 2013; San Francisco, CA.
19.
Wilken M, Huchzermeyer B. Suppression of mycelia formation by NO
produced endogenously in Candida tropicalis. Eur J Cell Biol 1999; 78: 209-13.
20.
Tao YP, Misko TP, Howlett AC, et al. Nitric oxide, an endogenous regulator
of Dictyostelium discoideum differentiation. Development 1997; 124: 3587-95.
21.
Thompson SE, Callow ME, Callow JA. The effects of nitric oxide in
settlement and adhesion of zoospores of the green alga Ulva. Biofouling 2010; 26:
167-78.

